A study to assess the effect of 3-month therapy of Ubidecarenone in treating cancer drug induced muscle wasting.
- Conditions
- Health Condition 1: R64- Cachexia
- Registration Number
- CTRI/2022/11/047338
- Lead Sponsor
- ADITYA VIKRAM SINGH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of either gender with age equal to or more than 18 years 2. Patients with diagnosis of any stage of cancer and receiving cisplatin based regimen 3. Patients having the ability to understand and sign a written informed consent document
1. Patient receiving concomitant medication(s) known to cause or aggravate cancer
chemotherapy induced cachexia
2. Patient receiving any other investigational agent
3. Psychological or sociological conditions, addictive disorders, or family problems that would
preclude adherence with study drug or compliance with the protocol
4. Difficulty while swallowing oral medications due to prolonged emesis, mucositis, esophageal
dysfunction, etc
5. History of allergy to Ubidecarenone
6. Patient with any infectious disease like TB, HIV-AIDS requiring pharmacotherapy
7. Patient with history of uncontrolled co-morbid conditions like diabetes mellitus,
hypertension, chronic kidney disease, autoimmune diseases like amyloidosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in CASCO scale (Cachexia Score) rating and Body composition analysis of cancer chemotherapy induced cachexia patients after 3 months of interventionTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method Correlation of physical and biochemical parameters with severity of cancer chemotherapy induced cachexiaTimepoint: 3 months;Difference in Body Composition Analysis (BCA) of cancer chemotherapy induced cachexia patientsTimepoint: 3 months;Difference in Quality of Life score (QoL) of cancer chemotherapy induced cachexia patients using CASCO questionnaire (Cachexia Score questionnaire)Timepoint: 3 months;Levels of leptin in cancer chemotherapy induced cachexia patientsTimepoint: 3 months